Document and Entity Information
Document and Entity Information - shares | 3 Months Ended | |
Mar. 31, 2020 | Apr. 29, 2020 | |
Cover [Abstract] | ||
Entity Registrant Name | Minerva Neurosciences, Inc. | |
Entity Central Index Key | 0001598646 | |
Amendment Flag | false | |
Entity Current Reporting Status | Yes | |
Document Type | 10-Q | |
Document Fiscal Period Focus | Q1 | |
Document Period End Date | Mar. 31, 2020 | |
Current Fiscal Year End Date | --12-31 | |
Entity Filer Category | Accelerated Filer | |
Entity Small Business | true | |
Entity Emerging Growth Company | false | |
Entity Shell Company | false | |
Entity Interactive Data Current | Yes | |
Document Fiscal Year Focus | 2020 | |
Title of 12(b) Security | Common Stock, $0.0001 par value per share | |
Trading Symbol | NERV | |
Entity Tax Identification Number | 26-0784194 | |
Entity File Number | 001-36517 | |
Entity Address, Address Line One | 1601 Trapelo Road | |
Entity Address, Address Line Two | Suite 286 | |
Entity Address, City or Town | Waltham | |
Entity Address, State or Province | MA | |
Entity Incorporation, State or Country Code | DE | |
Entity Address, Postal Zip Code | 02451 | |
City Area Code | 617 | |
Local Phone Number | 600-7373 | |
Document Transition Report | false | |
Document Quarterly Report | true | |
Security Exchange Name | NASDAQ | |
Entity Common Stock, Shares Outstanding | 39,219,134 |
Condensed Consolidated Balance
Condensed Consolidated Balance Sheets (Unaudited) - USD ($) | Mar. 31, 2020 | Dec. 31, 2019 |
Current assets | ||
Cash and cash equivalents | $ 30,036,149 | $ 21,412,623 |
Marketable securities | 7,478,185 | 24,441,520 |
Restricted cash | 100,000 | 100,000 |
Prepaid expenses and other current assets | 851,864 | 1,182,483 |
Total current assets | 38,466,198 | 47,136,626 |
Equipment, net | 11,644 | 16,011 |
Other noncurrent assets | 14,808 | 14,808 |
Operating lease right-of-use assets | 223,503 | 261,952 |
In-process research and development | 15,200,000 | 15,200,000 |
Goodwill | 14,869,399 | 14,869,399 |
Total assets | 68,785,552 | 77,498,796 |
Current liabilities | ||
Accounts payable | 3,003,054 | 2,317,004 |
Accrued expenses and other current liabilities | 3,936,233 | 4,139,163 |
Operating leases | 178,765 | 172,901 |
Total current liabilities | 7,118,052 | 6,629,068 |
Deferred taxes | 1,803,356 | 1,803,356 |
Deferred revenue | 41,175,600 | 41,175,600 |
Noncurrent operating leases | 64,350 | 111,229 |
Total liabilities | 50,161,358 | 49,719,253 |
Commitments and contingencies (Note 8) | ||
Stockholders’ equity | ||
Preferred stock; $0.0001 par value; 100,000,000 shares authorized; none issued or outstanding as of March 31, 2020 and December 31, 2019, respectively | ||
Common stock; $0.0001 par value; 125,000,000 shares authorized; 39,219,134 and 39,084,121 shares issued and outstanding as of March 31, 2020 and December 31, 2019, respectively | 3,922 | 3,908 |
Additional paid-in capital | 317,507,655 | 314,511,853 |
Accumulated deficit | (298,887,383) | (286,736,218) |
Total stockholders’ equity | 18,624,194 | 27,779,543 |
Total liabilities and stockholders’ equity | $ 68,785,552 | $ 77,498,796 |
Condensed Consolidated Balanc_2
Condensed Consolidated Balance Sheets (Parenthetical) (Unaudited) - $ / shares | Mar. 31, 2020 | Dec. 31, 2019 |
Statement Of Financial Position [Abstract] | ||
Preferred stock, par value (in dollars per share) | $ 0.0001 | $ 0.0001 |
Preferred stock, shares authorized | 100,000,000 | 100,000,000 |
Preferred stock, shares issued | 0 | 0 |
Preferred stock, shares outstanding | 0 | 0 |
Common stock, par value (in dollars per share) | $ 0.0001 | $ 0.0001 |
Common stock, shares authorized | 125,000,000 | 125,000,000 |
Common stock, shares issued | 39,219,134 | 39,084,121 |
Common stock, shares outstanding | 39,219,134 | 39,084,121 |
Condensed Consolidated Statemen
Condensed Consolidated Statements of Operations (Unaudited) - USD ($) | 3 Months Ended | |
Mar. 31, 2020 | Mar. 31, 2019 | |
Expenses | ||
Research and development | $ 8,082,510 | $ 11,606,197 |
General and administrative | 4,189,068 | 4,705,674 |
Total expenses | 12,271,578 | 16,311,871 |
Loss from operations | (12,271,578) | (16,311,871) |
Foreign exchange losses | (9,392) | (6,313) |
Investment income | 129,805 | 490,984 |
Net loss | $ (12,151,165) | $ (15,827,200) |
Net loss per share, basic and diluted | $ (0.31) | $ (0.41) |
Weighted average shares outstanding, basic and diluted | 39,177,592 | 38,968,110 |
Condensed Consolidated Statem_2
Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($) | Total | Common Stock | Additional Paid-in Capital | Accumulated Deficit |
Balance at Dec. 31, 2018 | $ 90,264,769 | $ 3,894 | $ 304,813,603 | $ (214,552,728) |
Balance (in shares) at Dec. 31, 2018 | 38,937,971 | |||
Exercise of stock options | 525,000 | $ 9 | 524,991 | |
Exercise of stock options (in shares) | 87,500 | |||
Stock-based compensation | 2,461,699 | 2,461,699 | ||
Net loss | (15,827,200) | (15,827,200) | ||
Balance at Mar. 31, 2019 | 77,424,268 | $ 3,903 | 307,800,293 | (230,379,928) |
Balance (in shares) at Mar. 31, 2019 | 39,025,471 | |||
Balance at Dec. 31, 2019 | $ 27,779,543 | $ 3,908 | 314,511,853 | (286,736,218) |
Balance (in shares) at Dec. 31, 2019 | 39,084,121 | 39,084,121 | ||
Exercise of stock options | $ 797,629 | $ 14 | 797,615 | |
Exercise of stock options (in shares) | 135,013 | |||
Stock-based compensation | 2,198,187 | 2,198,187 | ||
Net loss | (12,151,165) | (12,151,165) | ||
Balance at Mar. 31, 2020 | $ 18,624,194 | $ 3,922 | $ 317,507,655 | $ (298,887,383) |
Balance (in shares) at Mar. 31, 2020 | 39,219,134 | 39,219,134 |
Condensed Consolidated Statem_3
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) | 3 Months Ended | |
Mar. 31, 2020 | Mar. 31, 2019 | |
Cash flows from operating activities: | ||
Net loss | $ (12,151,165) | $ (15,827,200) |
Adjustments to reconcile net loss to net cash used in operating activities: | ||
Depreciation and amortization | 4,367 | 4,367 |
Accretion of marketable securities premium | (64,959) | (242,708) |
Amortization of right-of-use assets | 38,449 | 34,622 |
Stock-based compensation expense | 2,198,187 | 2,461,699 |
Changes in operating assets and liabilities | ||
Prepaid expenses and other current assets | 330,619 | 851,715 |
Accounts payable | 686,050 | 1,225,897 |
Accrued expenses and other current liabilities | (202,930) | 1,911,423 |
Operating lease liabilities, current | 5,864 | 20,609 |
Operating lease liabilities, noncurrent | (46,879) | (41,016) |
Net cash used in operating activities | (9,202,397) | (9,600,592) |
Cash flows from investing activities: | ||
Proceeds from the maturity and redemption of marketable securities | 20,900,000 | 9,000,000 |
Purchase of marketable securities | (3,871,706) | (19,551,411) |
Net cash provided (used in) by investing activities | 17,028,294 | (10,551,411) |
Cash flows from financing activities: | ||
Proceeds from exercise of stock options | 797,629 | 525,000 |
Net cash provided by financing activities | 797,629 | 525,000 |
Net increase (decrease) in cash, cash equivalents and restricted cash | 8,623,526 | (19,627,003) |
Cash, cash equivalents and restricted cash | ||
Beginning of period | 21,512,623 | 50,334,871 |
End of period | 30,136,149 | 30,707,868 |
Reconciliation of the Condensed Consolidated Statements of Cash Flows to the Condensed Consolidated Balance Sheets | ||
Cash and cash equivalents | 30,036,149 | 30,607,868 |
Restricted cash | 100,000 | 100,000 |
Total cash, cash equivalents and restricted cash | $ 30,136,149 | $ 30,707,868 |
Nature of Operations and Liquid
Nature of Operations and Liquidity | 3 Months Ended |
Mar. 31, 2020 | |
Nature Of Operations And Liquidity Disclosure [Abstract] | |
Nature of Operations and Liquidity | NOTE 1 — NATURE OF OPERATIONS AND LIQUIDITY Nature of Operations Minerva Neurosciences, Inc. (“Minerva” or the “Company”) is a clinical-stage biopharmaceutical company focused on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The Company has acquired or in-licensed four development-stage proprietary compounds that it believes have innovative mechanisms of action and therapeutic profiles that may potentially address the unmet needs of patients with these diseases. The Company’s lead product candidate is roluperidone (also known as MIN-101), a compound the Company is developing for the treatment of schizophrenia. In addition, the Company’s portfolio includes seltorexant (also known as MIN-202 or JNJ-42847922), a compound the Company is co-developing with Janssen Pharmaceutica NV (“Janssen”) for the treatment of insomnia disorder and major depressive disorder (“MDD”); and MIN-301, a compound the Company is developing for the treatment of Parkinson’s disease. In November 2013, the Company merged with Sonkei Pharmaceuticals Inc. (“Sonkei”), a clinical-stage biopharmaceutical company and, in February 2014, the Company acquired Mind-NRG, a pre-clinical-stage biopharmaceutical company. The Company refers to these transactions as the Sonkei Merger and Mind-NRG Acquisition, respectively. The Company holds licenses to roluperidone and MIN-117 from Mitsubishi Tanabe Pharma Corporation (“MTPC”) with the rights to develop, sell and import roluperidone and MIN-117 globally, excluding most of Asia. With the acquisition of Mind-NRG, the Company obtained exclusive rights to develop and commercialize MIN-301. The Company has also entered into a co-development and license agreement with Janssen, for the exclusive right to commercialize, and the co-exclusive right (with Janssen and its affiliates) to use and develop seltorexant in the European Union, Switzerland, Liechtenstein, Iceland and Norway (the “Minerva Territory”), subject to certain royalty payments to Janssen, and royalty rights for any sales outside the Minerva Territory. Liquidity The accompanying condensed consolidated financial statements have been prepared as though the Company will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The Company has limited capital resources and has incurred recurring operating losses and negative cash flows from operations since inception. As of March 31, 2020, the Company has an accumulated deficit of approximately $298.9 million As of March 31, 2020, the Company had cash, cash equivalents, restricted cash, and marketable securities of $37.6 million. The Company believes that its existing cash, cash equivalents, restricted cash and marketable securities will be sufficient to meet its cash commitments for at least the next 12 months after the date that the condensed consolidated financial statements are issued. The process of drug development can be costly and the timing and outcomes of clinical trials is uncertain. The assumptions upon which the Company has based its estimates are routinely evaluated and may be subject to change. The actual amount of the Company’s expenditures will vary depending upon a number of factors including but not limited to the design, timing and duration of future clinical trials, the progress of the Company’s research and development programs, the resolution of the Company’s dispute with Janssen as described in Notes 5 and 8, the infrastructure to support a commercial enterprise, the cost of a commercial product launch, and the level of financial resources available. If it is determined that the Company is required to make a significant payment to Janssen, it may not have sufficient cash to make such payment and may be required to incur additional indebtedness or to raise additional funds via an equity financing in order to make such payment to Janssen. The Company has the ability to adjust its operating plan spending levels based on the timing of future clinical trials which will be predicated upon adequate funding to complete the trials. The Company will need to raise additional capital in order to continue to fund operations and fully fund later stage clinical development programs. The Company believes that it will be able to obtain additional working capital through equity financings or other arrangements to fund future operations; however, there can be no assurance that such additional financing, if available, can be obtained on terms acceptable to the Company. If the Company is unable to obtain such additional financing, future operations would need to be scaled back or discontinued. |
Significant Accounting Policies
Significant Accounting Policies | 3 Months Ended |
Mar. 31, 2020 | |
Accounting Policies [Abstract] | |
Significant Accounting Policies | NOTE 2 — SIGNIFICANT ACCOUNTING POLICIES Basis of presentation The interim condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim reporting and the requirements of the Securities and Exchange Commission (“SEC”) in accordance with Regulation S-X, Rule 8-03. Under those rules, certain notes and financial information that are normally required for annual financial statements can be condensed or omitted. In the opinion of the Company’s management, the accompanying financial statements contain all adjustments (consisting of items of a normal and recurring nature) necessary to present fairly the financial position as of March 31, 2020, the results of operations for the three months ended March 31, 2020 and 2019 and cash flows for the three months ended March 31, 2020 and 2019. The results of operations for the three months ended March 31, 2020 are not necessarily indicative of the results to be expected for the full year. When preparing financial statements in conformity with GAAP, management must make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. The consolidated balance sheet as of December 31, 2019 was derived from the audited annual financial statements. The accompanying unaudited condensed consolidated financial statements and notes thereto should be read in conjunction with the audited consolidated financial statements for the year ended December 31, 2019 included in the Company’s Annual Report on Form 10-K filed with the SEC on March 9, 2020. Consolidation The accompanying consolidated financial statements include the results of the Company and its wholly-owned subsidiaries, Mind-NRG Sarl and Minerva Neurosciences Securities Corporation. Intercompany transactions have been eliminated. Significant risks and uncertainties The Company’s operations are subject to a number of factors that can affect its operating results and financial condition. Such factors include, but are not limited to: the results of clinical testing and trial activities of the Company’s products, the Company’s ability to obtain regulatory approval to market its products, competition from products manufactured and sold or being developed by other companies, the price of, and demand for, Company products, the Company’s ability to negotiate favorable licensing or other manufacturing and marketing agreements for its products, and the Company’s ability to raise capital. The Company currently has no commercially approved products and there can be no assurance that the Company’s research and development will be successfully commercialized. Developing and commercializing a product requires significant time and capital and is subject to regulatory review and approval as well as competition from other biotechnology and pharmaceutical companies. The Company operates in an environment of rapid change and is dependent upon the continued services of its employees and consultants and obtaining and protecting intellectual property. Use of estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. Cash and cash equivalents Cash equivalents include short-term, highly-liquid instruments, consisting of money market accounts and short-term investments with maturities from the date of purchase of 90 days or less. The majority of cash and cash equivalents are maintained with major financial institutions in North America. Deposits with these financial institutions may exceed the amount of insurance provided on such deposits. These deposits may be redeemed upon demand which reduces counterparty performance risk. Restricted cash Cash accounts with any type of restriction are classified as restricted. The Company maintained restricted cash balances as collateral for corporate credit cards in the amount of $0.1 million at each of March 31, 2020 and December 31, 2019. Marketable securities Marketable securities consist of corporate and U.S. government debt securities maturing in five months or less. Based on the Company’s intentions regarding its marketable securities, all marketable securities are classified as held-to-maturity and are carried under the amortized cost approach. The Company’s investments in marketable securities are classified as Level 2 within the fair value hierarchy. As of March 31, 2020, remaining final maturities of marketable securities ranged from April 2020 to August 2020, with a weighted average remaining maturity of approximately 2.1 months. The following tables provide the amortized cost basis, aggregate fair value, unrealized gains/losses, and the net carrying value of investments in held-to-maturity securities as of March 31, 2020 and December 31, 2019: March 31, 2020 Amortized Aggregate Unrealized Unrealized Net Carrying Cost Fair Value Gains Losses Value Marketable securities: Commercial paper $ 7,478,185 $ 7,478,185 $ — $ — $ 7,478,185 Marketable securities total $ 7,478,185 $ 7,478,185 $ — $ — $ 7,478,185 December 31, 2019 Amortized Aggregate Unrealized Unrealized Net Carrying Cost Fair Value Gains Losses Value Marketable securities: Corporate bonds/notes $ 2,701,114 $ 2,700,678 $ 436 $ — $ 2,701,114 Commercial paper 19,245,921 19,245,921 — — 19,245,921 U.S. government agency securities 2,494,485 2,495,675 — (1,190 ) 2,494,485 Marketable securities total $ 24,441,520 $ 24,442,274 $ 436 $ (1,190 ) $ 24,441,520 Research and development costs Costs incurred in connection with research and development activities are expensed as incurred. These costs include licensing fees to use certain technology in the Company’s research and development projects as well as fees paid to consultants and various entities that perform certain research and testing on behalf of the Company and costs related to salaries, benefits, bonuses and stock-based compensation granted to employees in research and development functions. The Company determines expenses related to clinical studies based on estimates of the services received and efforts expended pursuant to contracts with multiple research institutions and contract research organizations (“CROs”) that conduct and manage clinical studies on its behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. Payments under some of these contracts depend on factors such as the successful enrollment of patients and the completion of clinical trial milestones. In accruing service fees, the Company estimates the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from the estimate, the accrual is adjusted accordingly. The expenses for some trials may be recognized on a straight-line basis if the anticipated costs are expected to be incurred ratably during the period. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the consolidated financial statements as prepaid or accrued expenses. In-process research and development In-process research and development (“IPR&D”) assets represent capitalized incomplete research projects that the Company acquired through business combinations. Such assets are initially measured at their acquisition date fair values. The initial fair value of the research projects are recorded as intangible assets on the balance sheet, rather than expensed, regardless of whether these assets have an alternative future use. The amounts capitalized are being accounted for as indefinite-lived intangible assets, subject to impairment testing, until completion or abandonment of research and development efforts associated with the project. An IPR&D asset is considered abandoned when it ceases to be used (that is, research and development efforts associated with the asset have ceased, and there are no plans to sell or license the asset or derive defensive value from the asset). At that point, the asset is considered to be disposed of and is written off. Upon successful completion of each project, the Company will make a determination about the then remaining useful life of the intangible asset and begin amortization. The Company tests its indefinite-lived intangibles, IPR&D assets, for impairment annually on November 30 and more frequently if events or changes in circumstances indicate that it is more likely than not that the asset is impaired. When testing indefinite-lived intangibles for impairment, the Company may assess qualitative factors for its indefinite-lived intangibles to determine whether it is more likely than not (that is, a likelihood of more than 50 percent) that the asset is impaired. Alternatively, the Company may bypass this qualitative assessment for some or all of its indefinite-lived intangibles and perform the quantitative impairment test that compares the fair value of the indefinite-lived intangible asset with the asset’s carrying amount. There was no impairment of IPR&D for the three months ended March 31, 2020 or 2019. Impairment of MIN-117 In-process Research and Development Asset. As a result of the Company’s Phase 2b trial of MIN-117 in adult patients suffering from moderate to severe MDD not meeting its primary and key secondary endpoints and the Company’s decision not to further the clinical development of MIN-117 in MDD, the Company determined that the MIN-117 IPR&D is fully impaired and recognized a $19.0 million expense, which was included as a component of research and development expense, during the year ended December 31, 2019. Stock-based compensation The Company recognizes compensation cost relating to stock-based payment transactions using a fair-value measurement method, which requires all stock-based payments to employees, including grants of employee stock options, to be recognized in operating results as compensation expense based on fair value over the requisite service period of the awards. The Company determines the fair value of stock-based awards using the Black-Scholes option-pricing model which uses both historical and current market data to estimate fair value. The method incorporates various assumptions such as the risk-free interest rate, expected volatility, expected dividend yield, and expected life of the options. Forfeitures are recorded as they occur instead of estimating forfeitures that are expected to occur. The fair value of restricted stock units (“RSUs”) is equal to the closing price of the Company’s common stock on the date of grant. An accounting policy change was made by the Company related to the accounting for non-employee awards on January 1, 2019 as a result of the adoption of ASU No. 2018-07, Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting The date of expense recognition for grants to non-employees is the earlier of the date at which a commitment for performance by the counterparty to earn the equity instrument is reached or the date at which the counterparty’s performance is complete. The Company determines the fair value of stock-based awards granted to non-employees similar to the way fair value of awards are determined for employees except that certain assumptions used in the Black-Scholes option-pricing model, such as expected life of the option, may be different. Foreign currency transactions The Company’s functional currency is the U.S. Dollar. The Company pays certain vendor invoices in the respective foreign currency. The Company records an expense in U.S. Dollars at the time the liability is incurred. Changes in the applicable foreign currency rate between the date an expense is recorded and the payment date is recorded as a foreign currency gain or loss. Loss per share Basic loss per share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding for the period. Diluted loss per share reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that shared in the earnings of the entity. The treasury stock method is used to determine the dilutive effect of the Company’s stock options and warrants. The Company had a net loss in all periods presented, thus the inclusion of stock options and warrants would be anti-dilutive to net loss per share. Concentration of credit risk Financial instruments that potentially subject the Company to concentrations of credit risk are primarily cash, cash equivalents and marketable securities. The Company maintains its cash and cash equivalent balances in the form of business checking accounts and money market accounts, the balances of which, at times, may exceed federally insured limits. Exposure to cash and cash equivalents credit risk is reduced by placing such deposits with major financial institutions and monitoring their credit ratings. Marketable securities consist primarily of corporate bonds, with fixed interest rates. Exposure to credit risk of marketable securities is reduced by maintaining a diverse portfolio and monitoring their credit ratings. Equipment Equipment is stated at cost less accumulated depreciation. Equipment is depreciated on the straight-line basis over their estimated useful lives of three years. Expenditures for maintenance and repairs are charged to expense as incurred. Leases Effective January 1, 2019, the Company adopted Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 842, Leases Leases At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present in the arrangement. Most leases with a term greater than one year are recognized on the balance sheet as right-of-use assets and short-term and long-term lease liabilities, as applicable. The Company has elected not to recognize on the balance sheet leases with terms of 12 months or less. The Company typically only includes an initial lease term in its assessment of a lease arrangement. Options to renew a lease are not included in the Company’s assessment unless there is reasonable certainty that the Company will renew. The Company monitors its plans to renew its material leases on a quarterly basis. Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected remaining lease term. Certain adjustments to the right-of-use asset may be required for items such as incentives received. The interest rate implicit in the Company’s leases is typically not readily determinable. As a result, the Company utilizes its incremental borrowing rate, which reflects the fixed rate at which the Company could borrow on a collateralized basis the amount of the lease payments in the same currency, for a similar term and in a similar economic environment. In transition to ASC 842, the Company utilized the remaining lease term of its leases in determining the appropriate incremental borrowing rates. In accordance with ASC 842, components of a lease should be allocated between lease components (e.g., land, building, etc.) and non-lease components (e.g., common area maintenance, consumables, etc.). The fixed and in-substance fixed contract consideration (including any consideration related to non-components) must be allocated based on the respective relative fair values to the lease components and non-lease components. Although separation of lease and non-lease components is required, certain expedients are available. Entities may elect the practical expedient to not separate lease and non-lease components by class of underlying asset where entities would account for each lease component and the related non-lease component together as a single component. For new and amended leases beginning in 2019 and after, the Company has elected to account for the lease and non-lease components for leases for classes of all underlying assets and allocate all of the contract consideration to the lease component only. Long-lived assets The Company reviews the recoverability of all long-lived assets, including the related useful lives, whenever events or changes in circumstances indicate that the carrying amount of a long-lived asset might not be recoverable. If required, the Company compares the estimated undiscounted future net cash flows to the related asset’s carrying value to determine whether there has been an impairment. If an asset is considered impaired, the asset is written down to fair value, which is based either on discounted cash flows or appraised values in the period the impairment becomes known. The Company believes that all long-lived assets are recoverable, and no impairment was deemed necessary at March 31, 2020 and 2019. Goodwill The Company tests its goodwill for impairment annually, or whenever events or changes in circumstances indicate an impairment may have occurred, by comparing its reporting unit’s carrying value to its fair value. Impairment may result from, among other things, deterioration in the performance of the acquired business, adverse market conditions, adverse changes in applicable laws or regulations and a variety of other circumstances. If the Company determines that an impairment has occurred, it is required to record a write-down of the carrying value and charge the impairment as an operating expense in the period the determination is made. In evaluating the recoverability of the carrying value of goodwill, the Company must make assumptions regarding estimated future cash flows and other factors to determine the fair value of the acquired assets. Changes in strategy or market conditions could significantly impact those judgments in the future and require an adjustment to the recorded balances. The Company tests its goodwill for impairment as of November 30. There was no impairment of goodwill for the three months ended March 31, 2020 and 2019. Revenue recognition The Company applies the revenue recognition guidance in accordance with ASC 606, Revenue from Contracts with Customers When the Company enters into an arrangement that meets the definition of a collaboration under ASC 808, Collaborative Arrangements Deferred revenue The Company applies the revenue recognition guidance in accordance with ASC 606. Using ASC 606, revenue that is unearned is deferred. Deferred revenue that is expected to be recognized as revenue more than one year subsequent to the balance sheet date is classified as long-term deferred revenue. Segment information Operating segments are defined as components of an enterprise (business activity from which it earns revenue and incurs expenses) about which discrete financial information is available and regularly reviewed by the chief operating decision maker in deciding how to allocate resources and in assessing performance. The Company’s chief decision maker, who is the Chief Executive Officer, reviews operating results to make decisions about allocating resources and assessing performance for the entire Company. The Company views its operations and manages its business as one operating segment. Comprehensive loss The Company had no items of comprehensive loss other than its net loss for each period presented. Recent accounting pronouncements From time to time, new accounting pronouncements are issued by the FASB and are adopted by the Company as of the specified effective date. Recently adopted accounting pronouncements In November 2018, the FASB issued ASU 2018-18, Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606 In January 2017, the FASB issued ASU No. 2017-04, Intangibles — Goodwill and Other (Topic 350). |
Accrued Expenses and Other Liab
Accrued Expenses and Other Liabilities | 3 Months Ended |
Mar. 31, 2020 | |
Payables And Accruals [Abstract] | |
Accrued Expenses and Other Liabilities | NOTE 3 — ACCRUED EXPENSES AND OTHER LIABILITIES Accrued expenses and other liabilities consist of the following: March 31, 2020 December 31, 2019 Research and development costs and other accrued expenses $ 3,090,336 $ 3,824,950 Accrued bonus 504,600 — Professional fees 281,050 314,213 Vacation pay 60,247 — $ 3,936,233 $ 4,139,163 |
Net Loss Per Share of Common St
Net Loss Per Share of Common Stock | 3 Months Ended |
Mar. 31, 2020 | |
Earnings Per Share [Abstract] | |
Net Loss Per Share of Common Stock | NOTE 4 — NET LOSS PER SHARE OF COMMON STOCK Diluted loss per share is the same as basic loss per share for all periods presented as the effects of potentially dilutive items were anti-dilutive given the Company’s net loss. Basic loss per share is computed by dividing net loss by the weighted-average number of common shares outstanding. The following table sets forth the computation of basic and diluted loss per share for common stockholders: Three Months Ended March 31, 2020 2019 Net loss $ (12,151,165 ) $ (15,827,200 ) Weighted average shares of common stock outstanding 39,177,592 38,968,110 Net loss per share of common stock – basic and diluted $ (0.31 ) $ (0.41 ) The following securities outstanding at March 31, 2020 and 2019 have been excluded from the calculation of weighted average shares outstanding as their effect on the calculation of loss per share is antidilutive: Three Months Ended March 31, 2020 2019 Common stock options 8,799,959 8,378,672 Restricted stock units 68,650 127,300 Common stock warrants 40,790 40,790 |
Co-Development and License Agre
Co-Development and License Agreement | 3 Months Ended |
Mar. 31, 2020 | |
Co Development And License Agreement Disclosure [Abstract] | |
Co-Development and License Agreement | NOTE 5 — CO-DEVELOPMENT AND LICENSE AGREEMENT On February 13, 2014, the Company signed a co-development and license agreement (the “Agreement”) which became effective upon seltorexant seltorexant The Company accounts for the Agreement as a joint risk-sharing collaboration in accordance with ASC 808, Collaborative Arrangements On July 6, 2016, the Company and Janssen agreed that “Decision Point 2” had been reached as defined under the Agreement. As neither party exercised their right to withdraw from the Agreement, the Company paid Janssen $3.5 million and has incurred direct expenses of $0.3 million related to development activities under the current phase of development. During the three months ended March 31, 2020 and 2019 the Company recorded an expense of zero for certain development activities in accordance with the terms of the Agreement. In June 2017, the Company entered into an amendment (“the Amendment”) to the Agreement. The effectiveness of the Amendment was contingent upon approval of its terms by the European Commission and the closing of the acquisition of Actelion Ltd. by affiliates of Janssen. These conditions were subsequently met, and the Amendment became effective on August 29, 2017. Under the Amendment, Janssen has waived its right to royalties on seltorexant insomnia sales in the Minerva Territory. The Company retains all of its rights to seltorexant, including commercialization of the molecule for the treatment of insomnia and as an adjunctive therapy for MDD, which include an exclusive license in the Minerva Territory, with royalties payable by the Company to Janssen on seltorexant sales outside of the insomnia indication. Royalties on sales outside of the Minerva Territory are payable by Janssen to the Company. Janssen made an upfront payment to the Company of $30 million upon the effectiveness of the Amendment and agreed to make a $20 million payment at the start of a Phase 3 insomnia trial for seltorexant and a $20 million payment when 50% of the patients are enrolled in this trial. Janssen further agreed to waive development payments from the Company until completion of the Phase 2b development milestone, which is referred to as “Decision Point 4”. Top-line results have been reported from three Phase 2b trials and one Phase 1b trial with seltorexant. The $30 million payment and $11.2 million in previously accrued collaborative expenses, which were forgiven upon the effective date of the Amendment, are earned and recognized as revenue as the services are performed from the commencement of Phase 3 development to the completion of the development activities using the proportional performance method. The $30 million payment along with the $11.2 million in previously accrued collaborative expenses have been included under deferred revenue on the Company’s balance sheet at March 31, 2020 and December 31, 2019. If the Company opts out of the program, then any remaining deferred revenue would be recognized at the time of the opt out. In connection with the Amendment, the Company repurchased all of the approximately 3.9 million shares of its common stock previously owned by Johnson & Johnson Innovation-JJDC Inc. at a per share price of $0.0001, for an aggregate purchase price of approximately $389. As a result of the Amendment, the Company assumed strategic control of matters relating to the clinical development of seltorexant for insomnia and has no further financial obligations until after Decision Point 4. After Decision Point 4, both the Company and Janssen have the right to opt-out of the Agreement. If both parties elect to continue past Decision Point 4 into Phase 3, the Company would be obligated to fund the clinical trials related to insomnia, receive up to $40 million in milestone payments from Janssen, and be responsible for 40% of all costs incurred in the MDD program. After reviewing the data from the Phase 2b trials already conducted, the Company is not in agreement with Janssen that Decision Point 4 under the Agreement has been reached. Under the Agreement, the Company’s cost-sharing obligations do not begin until Decision Point 4 has been reached. The Company has the right to opt-out of the Agreement at any time after Decision Point 4, and if it opts-out, the Company will collect a royalty on worldwide sales of seltorexant in the mid-single digits with no further obligations to Janssen. If Janssen opts-out, the Minerva Territory would expand to include North America and the Company would pay Janssen single digit royalties on sales of seltorexant outside of the insomnia indication. In January 2020, Janssen invoiced the Company $3.4 million, representing the Company’s 40% portion of the Phase 3 development costs through December 31, 2019. In April 2020, Janssen invoiced the Company an additional $3.1 million, for a cumulative total through March 31, 2020 of $6.5 million. Janssen has previously indicated they may incur approximately $100 million in Phase 3 development costs in 2020. The Company has been conducting discussions with Janssen regarding this disagreement and the Company has not accrued any Phase 3 development costs incurred by Janssen (See Note 8). The Company determined that the license under the Amendment is not considered to be a separate deliverable as it contains no value without the development activities performed under the Agreement. The participation in the joint steering committee under the Amendment is considered to be not separable from the development activities and therefore the two deliverables are combined into a single unit of account. The Company concluded that the milestone payments are related to future performance obligations and will be recognized as those performance obligations are performed by the Company. Similarly, the Company will recognize royalty revenues in the periods of the sale of the related products, provided that no future performance obligations exist and revenue recognition is limited to amounts for which it is probable that a significant reversal will not occur. |
Stockholders' Equity
Stockholders' Equity | 3 Months Ended |
Mar. 31, 2020 | |
Stockholders Equity Note [Abstract] | |
Stockholders' Equity | NOTE 6 — STOCKHOLDERS’ EQUITY Term Loan Warrants In connection with the Company’s former Loan and Security Agreement with Oxford Finance LLC and Silicon Valley Bank (the “Lenders”), which provided for term loans to the Company in an aggregate principal amount of up to $15 million in two tranches on January 15, 2016, the Company issued the Lenders warrants to purchase 40,790 shares of common stock at a per share exercise price of $5.516. The warrants are immediately exercisable upon issuance, and other than in connection with certain mergers or acquisitions, will expire on the ten-year anniversary of the date of issuance. The fair value of the warrants was estimated at $0.2 million using a Black-Scholes model and assuming: (i) expected volatility of 100.8%, (ii) risk free interest rate of 1.83%, (iii) an expected life of 10 years and (iv) no dividend payments. The fair value of the warrants was included as a discount to the term loans drawn at such time and also as a component of additional paid-in capital and were amortized to interest expense over the term of the loan. Although the term loans were repaid in August 2018, all related warrants were outstanding and exercisable as of March 31, 2020. |
Stock Award Plan and Stock-Base
Stock Award Plan and Stock-Based Compensation | 3 Months Ended |
Mar. 31, 2020 | |
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract] | |
Stock Award Plan and Stock-Based Compensation | NOTE 7 — STOCK AWARD PLAN AND STOCK-BASED COMPENSATION In December 2013, the Company adopted the 2013 Equity Incentive Plan (as subsequently amended and restated, the “Plan”), which provides for the issuance of options, stock appreciation rights, stock awards and stock units. Pursuant to Nasdaq listing rules, the Company issued inducement awards in December 2017 to the Company’s President outside of the Plan in the form of an option to purchase 775,000 shares of the Company’s common stock and a RSU award to purchase 40,000 shares of the Company’s common stock. In June 2018, the Company increased the aggregate number of shares of common stock authorized for issuance under the Plan by 2,500,000 shares. Stock option activity for employees and non-employees for the three months ended March 31, 2020 is as follows: Shares Issuable Pursuant to Stock Options Weighted- Average Exercise Price Weighted- Average Remaining Contractual Terms (years) Total Intrinsic Value (in thousands) Outstanding January 1, 2020 9,040,328 $ 6.98 7.3 $ 7,420 Granted — $ — Exercised (135,013 ) $ 5.91 Forfeited (105,356 ) $ 9.63 Outstanding March 31, 2020 8,799,959 $ 6.96 7.1 $ 1,625 Exercisable March 31, 2020 5,614,559 $ 6.69 6.4 $ 1,586 Available for future grant 245,354 The weighted average grant-date fair value of stock options outstanding on March 31, 2020 was $5.01 per share. Total unrecognized compensation costs related to non-vested stock options at March 31, 2020 were approximately $15.8 million and are expected to be recognized within future operating results over a weighted-average period of 2.29 years. The total intrinsic value of the options exercised during the three months ended March 31, 2020, and 2019 was approximately $0.3 million and $0.2 million, respectively. The expected term of the employee-related options was estimated using the “simplified” method as defined by the SEC’s Staff Accounting Bulletin No. 107, Share-Based Payment The Company uses the Black-Scholes model to estimate the fair value of stock options granted. There were no stock options granted during the three months ended March 31, 2020, and 2019. RSU activity under the Plan for the three months ended March 31, 2020 is as follows: Weighted- Average Grant Date RSUs Fair Value Unvested January 1, 2020 68,650 $ 11.29 Granted — $ — Vested — $ — Forfeited — $ — Unvested March 31, 2020 68,650 $ 11.29 RSUs awarded to employees generally vest one-fourth per year over four years from the anniversary of the date of grant, provided the employee remains continuously employed with the Company. Shares of the Company’s stock are delivered to the employee upon vesting, subject to payment of applicable withholding taxes. The fair value of RSUs is equal to the closing price of the Company’s common stock on the date of grant. Total unrecognized compensation costs related to non-vested RSUs at March 31, 2020 was approximately $0.6 million and is expected to be recognized within future operating results over a period of 0.9 years. The following table presents stock-based compensation expense included in the Company’s consolidated statements of operations: Three Months Ended March 31, 2020 2019 Research and development $ 681,613 $ 700,263 General and administrative 1,516,574 1,761,436 Total $ 2,198,187 $ 2,461,699 |
Commitments and Contingencies
Commitments and Contingencies | 3 Months Ended |
Mar. 31, 2020 | |
Commitments And Contingencies Disclosure [Abstract] | |
Commitments and Contingencies | NOTE 8 — COMMITMENTS AND CONTINGENCIES From time to time, the Company may be subject to various legal proceedings and claims that arise in the ordinary course of the Company’s business activities. While the outcome of these claims cannot be predicted with certainty, management does not believe that the outcome of any of these other legal matters will have a material adverse effect on the Company’s consolidated financial statements. Disagreement with Janssen After reviewing the data from the Phase 2b trials already conducted, the Company is not in agreement with Janssen that Decision Point 4 under the Agreement has been reached. Under the Agreement, the Company’s cost-sharing obligations do not begin until Decision Point 4 has been reached. Following occurrence of Decision Point 4, Janssen is responsible for 60% of the cost of Phase 3 development in all indications except insomnia and the Company is responsible for 40%. The Company has the right to opt-out of the Agreement at any time after Decision Point 4, and if it opts-out, the Company will collect a royalty on worldwide sales of seltorexant in the mid-single digits with no further obligations to Janssen. In January 2020, Janssen invoiced the Company $3.4 million, representing the Company’s 40% portion of the Phase 3 development costs through December 31, 2019. In April 2020, Janssen invoiced the Company an additional $3.1 million, for a cumulative total through March 31, 2020 of $6.5 million. Janssen has previously indicated they may incur approximately $100 million in Phase 3 development costs in 2020. The Company has been conducting discussions with Janssen regarding this disagreement and the Company has not accrued any Phase 3 development costs incurred by Janssen. Refer to Note 9 – Leases, for the Company’s current lease commitments. |
Leases
Leases | 3 Months Ended |
Mar. 31, 2020 | |
Leases [Abstract] | |
Leases | NOTE 9 — LEASES Operating leases On October 2, 2017, the Company entered into an office sublease agreement (the “Sublease”) with Profitect, Inc. (the “Sublandlord”) to sublease approximately 5,923 rentable square feet of office space located at 1601 Trapelo Road, Waltham, MA 02451 (the “Premises”). The term of the Sublease began on November 1, 2017 and will expire on July 31, 2021 (the “Term”), with a monthly rental rate starting at $14,808 and escalating to a maximum monthly rental rate of $16,288 in the final 12 months of the Term. The Sublandlord provided the Premises to the Company free of charge for the first two months of the Term. The Company will recognize the remaining expense in accordance with ASC 842. Throughout the Term, the Company is responsible for paying certain costs and expenses, in addition to the rent, as specified in the Sublease, including a proportionate share of applicable taxes, operating expenses and utilities. In applying the ASC 842 transition guidance, the Company retained the classification of this Sublease as operating and recorded a lease liability and a right-of-use asset on the ASC 842 effective date. The following table contains a summary of the Sublease costs recognized under ASC 842 and other information pertaining to the Company’s operating Sublease for the three months ended March 31, 2020: Three Months Ended March 31, 2020 Sublease cost Operating Sublease cost $ 44,817 Total Sublease cost $ 44,817 Other information Operating cash flows used for operating Sublease $ 47,384 Weighted average remaining Sublease term 1.3 years Weighted average discount rate 10% Future minimum Sublease payments under the Company’s non-cancelable operating Sublease as of March 31, 2020 and December 31, 2019 are as follows: Future Operating Sublease Payments Three Months Ended March 31, 2020 2020 (excluding the three months ended March 31, 2020) 144,620 2021 114,018 Thereafter — Total Sublease payments $ 258,638 Less: imputed interest (15,523 ) Total operating Sublease liabilities at March 31, 2020 $ 243,115 Future Operating Sublease Payments Year Ended December 31, 2019 2020 192,004 2021 114,018 Thereafter — Total Sublease payments $ 306,022 Less: imputed interest (21,892 ) Total operating Sublease liabilities at December 31, 2019 $ 284,130 |
Related Party Transactions
Related Party Transactions | 3 Months Ended |
Mar. 31, 2020 | |
Related Party Transactions [Abstract] | |
Related Party Transactions | NOTE 10 — RELATED PARTY TRANSACTIONS In January 2016, the Company entered into a services agreement with V-Watch SA (“V-Watch”), for approximately $105 thousand for the use of V-Watch’s SomnoArt device for monitoring sleep in the roluperidone Phase 2b and MIN-117 Phase 2a trials. The Company’s Chief Executive Officer is the chairman of the board of directors of V-Watch. Funds affiliated with Index Ventures, a stockholder of the Company, hold greater than 10% of the outstanding capital stock of V-Watch. Also refer to Note 5 – Co-Development and License Agreement for additional related party transactions. |
Significant Accounting Polici_2
Significant Accounting Policies (Policies) | 3 Months Ended |
Mar. 31, 2020 | |
Accounting Policies [Abstract] | |
Basis of Presentation | Basis of presentation The interim condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim reporting and the requirements of the Securities and Exchange Commission (“SEC”) in accordance with Regulation S-X, Rule 8-03. Under those rules, certain notes and financial information that are normally required for annual financial statements can be condensed or omitted. In the opinion of the Company’s management, the accompanying financial statements contain all adjustments (consisting of items of a normal and recurring nature) necessary to present fairly the financial position as of March 31, 2020, the results of operations for the three months ended March 31, 2020 and 2019 and cash flows for the three months ended March 31, 2020 and 2019. The results of operations for the three months ended March 31, 2020 are not necessarily indicative of the results to be expected for the full year. When preparing financial statements in conformity with GAAP, management must make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. The consolidated balance sheet as of December 31, 2019 was derived from the audited annual financial statements. The accompanying unaudited condensed consolidated financial statements and notes thereto should be read in conjunction with the audited consolidated financial statements for the year ended December 31, 2019 included in the Company’s Annual Report on Form 10-K filed with the SEC on March 9, 2020. |
Consolidation | Consolidation The accompanying consolidated financial statements include the results of the Company and its wholly-owned subsidiaries, Mind-NRG Sarl and Minerva Neurosciences Securities Corporation. Intercompany transactions have been eliminated. |
Significant Risks and Uncertainties | Significant risks and uncertainties The Company’s operations are subject to a number of factors that can affect its operating results and financial condition. Such factors include, but are not limited to: the results of clinical testing and trial activities of the Company’s products, the Company’s ability to obtain regulatory approval to market its products, competition from products manufactured and sold or being developed by other companies, the price of, and demand for, Company products, the Company’s ability to negotiate favorable licensing or other manufacturing and marketing agreements for its products, and the Company’s ability to raise capital. The Company currently has no commercially approved products and there can be no assurance that the Company’s research and development will be successfully commercialized. Developing and commercializing a product requires significant time and capital and is subject to regulatory review and approval as well as competition from other biotechnology and pharmaceutical companies. The Company operates in an environment of rapid change and is dependent upon the continued services of its employees and consultants and obtaining and protecting intellectual property. |
Use of Estimates | Use of estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. |
Cash and Cash Equivalents | Cash and cash equivalents Cash equivalents include short-term, highly-liquid instruments, consisting of money market accounts and short-term investments with maturities from the date of purchase of 90 days or less. The majority of cash and cash equivalents are maintained with major financial institutions in North America. Deposits with these financial institutions may exceed the amount of insurance provided on such deposits. These deposits may be redeemed upon demand which reduces counterparty performance risk. |
Restricted Cash | Restricted cash Cash accounts with any type of restriction are classified as restricted. The Company maintained restricted cash balances as collateral for corporate credit cards in the amount of $0.1 million at each of March 31, 2020 and December 31, 2019. |
Marketable Securities | Marketable securities Marketable securities consist of corporate and U.S. government debt securities maturing in five months or less. Based on the Company’s intentions regarding its marketable securities, all marketable securities are classified as held-to-maturity and are carried under the amortized cost approach. The Company’s investments in marketable securities are classified as Level 2 within the fair value hierarchy. As of March 31, 2020, remaining final maturities of marketable securities ranged from April 2020 to August 2020, with a weighted average remaining maturity of approximately 2.1 months. The following tables provide the amortized cost basis, aggregate fair value, unrealized gains/losses, and the net carrying value of investments in held-to-maturity securities as of March 31, 2020 and December 31, 2019: March 31, 2020 Amortized Aggregate Unrealized Unrealized Net Carrying Cost Fair Value Gains Losses Value Marketable securities: Commercial paper $ 7,478,185 $ 7,478,185 $ — $ — $ 7,478,185 Marketable securities total $ 7,478,185 $ 7,478,185 $ — $ — $ 7,478,185 December 31, 2019 Amortized Aggregate Unrealized Unrealized Net Carrying Cost Fair Value Gains Losses Value Marketable securities: Corporate bonds/notes $ 2,701,114 $ 2,700,678 $ 436 $ — $ 2,701,114 Commercial paper 19,245,921 19,245,921 — — 19,245,921 U.S. government agency securities 2,494,485 2,495,675 — (1,190 ) 2,494,485 Marketable securities total $ 24,441,520 $ 24,442,274 $ 436 $ (1,190 ) $ 24,441,520 |
Research and Development Costs | Research and development costs Costs incurred in connection with research and development activities are expensed as incurred. These costs include licensing fees to use certain technology in the Company’s research and development projects as well as fees paid to consultants and various entities that perform certain research and testing on behalf of the Company and costs related to salaries, benefits, bonuses and stock-based compensation granted to employees in research and development functions. The Company determines expenses related to clinical studies based on estimates of the services received and efforts expended pursuant to contracts with multiple research institutions and contract research organizations (“CROs”) that conduct and manage clinical studies on its behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. Payments under some of these contracts depend on factors such as the successful enrollment of patients and the completion of clinical trial milestones. In accruing service fees, the Company estimates the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from the estimate, the accrual is adjusted accordingly. The expenses for some trials may be recognized on a straight-line basis if the anticipated costs are expected to be incurred ratably during the period. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the consolidated financial statements as prepaid or accrued expenses. |
In-Process Research and Development | In-process research and development In-process research and development (“IPR&D”) assets represent capitalized incomplete research projects that the Company acquired through business combinations. Such assets are initially measured at their acquisition date fair values. The initial fair value of the research projects are recorded as intangible assets on the balance sheet, rather than expensed, regardless of whether these assets have an alternative future use. The amounts capitalized are being accounted for as indefinite-lived intangible assets, subject to impairment testing, until completion or abandonment of research and development efforts associated with the project. An IPR&D asset is considered abandoned when it ceases to be used (that is, research and development efforts associated with the asset have ceased, and there are no plans to sell or license the asset or derive defensive value from the asset). At that point, the asset is considered to be disposed of and is written off. Upon successful completion of each project, the Company will make a determination about the then remaining useful life of the intangible asset and begin amortization. The Company tests its indefinite-lived intangibles, IPR&D assets, for impairment annually on November 30 and more frequently if events or changes in circumstances indicate that it is more likely than not that the asset is impaired. When testing indefinite-lived intangibles for impairment, the Company may assess qualitative factors for its indefinite-lived intangibles to determine whether it is more likely than not (that is, a likelihood of more than 50 percent) that the asset is impaired. Alternatively, the Company may bypass this qualitative assessment for some or all of its indefinite-lived intangibles and perform the quantitative impairment test that compares the fair value of the indefinite-lived intangible asset with the asset’s carrying amount. There was no impairment of IPR&D for the three months ended March 31, 2020 or 2019. Impairment of MIN-117 In-process Research and Development Asset. As a result of the Company’s Phase 2b trial of MIN-117 in adult patients suffering from moderate to severe MDD not meeting its primary and key secondary endpoints and the Company’s decision not to further the clinical development of MIN-117 in MDD, the Company determined that the MIN-117 IPR&D is fully impaired and recognized a $19.0 million expense, which was included as a component of research and development expense, during the year ended December 31, 2019. |
Stock-Based Compensation | Stock-based compensation The Company recognizes compensation cost relating to stock-based payment transactions using a fair-value measurement method, which requires all stock-based payments to employees, including grants of employee stock options, to be recognized in operating results as compensation expense based on fair value over the requisite service period of the awards. The Company determines the fair value of stock-based awards using the Black-Scholes option-pricing model which uses both historical and current market data to estimate fair value. The method incorporates various assumptions such as the risk-free interest rate, expected volatility, expected dividend yield, and expected life of the options. Forfeitures are recorded as they occur instead of estimating forfeitures that are expected to occur. The fair value of restricted stock units (“RSUs”) is equal to the closing price of the Company’s common stock on the date of grant. An accounting policy change was made by the Company related to the accounting for non-employee awards on January 1, 2019 as a result of the adoption of ASU No. 2018-07, Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting The date of expense recognition for grants to non-employees is the earlier of the date at which a commitment for performance by the counterparty to earn the equity instrument is reached or the date at which the counterparty’s performance is complete. The Company determines the fair value of stock-based awards granted to non-employees similar to the way fair value of awards are determined for employees except that certain assumptions used in the Black-Scholes option-pricing model, such as expected life of the option, may be different. |
Foreign Currency Transactions | Foreign currency transactions The Company’s functional currency is the U.S. Dollar. The Company pays certain vendor invoices in the respective foreign currency. The Company records an expense in U.S. Dollars at the time the liability is incurred. Changes in the applicable foreign currency rate between the date an expense is recorded and the payment date is recorded as a foreign currency gain or loss. |
Loss Per Share | Loss per share Basic loss per share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding for the period. Diluted loss per share reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that shared in the earnings of the entity. The treasury stock method is used to determine the dilutive effect of the Company’s stock options and warrants. The Company had a net loss in all periods presented, thus the inclusion of stock options and warrants would be anti-dilutive to net loss per share. |
Concentration of Credit Risk | Concentration of credit risk Financial instruments that potentially subject the Company to concentrations of credit risk are primarily cash, cash equivalents and marketable securities. The Company maintains its cash and cash equivalent balances in the form of business checking accounts and money market accounts, the balances of which, at times, may exceed federally insured limits. Exposure to cash and cash equivalents credit risk is reduced by placing such deposits with major financial institutions and monitoring their credit ratings. Marketable securities consist primarily of corporate bonds, with fixed interest rates. Exposure to credit risk of marketable securities is reduced by maintaining a diverse portfolio and monitoring their credit ratings. |
Equipment | Equipment Equipment is stated at cost less accumulated depreciation. Equipment is depreciated on the straight-line basis over their estimated useful lives of three years. Expenditures for maintenance and repairs are charged to expense as incurred. |
Leases | Leases Effective January 1, 2019, the Company adopted Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 842, Leases Leases At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present in the arrangement. Most leases with a term greater than one year are recognized on the balance sheet as right-of-use assets and short-term and long-term lease liabilities, as applicable. The Company has elected not to recognize on the balance sheet leases with terms of 12 months or less. The Company typically only includes an initial lease term in its assessment of a lease arrangement. Options to renew a lease are not included in the Company’s assessment unless there is reasonable certainty that the Company will renew. The Company monitors its plans to renew its material leases on a quarterly basis. Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected remaining lease term. Certain adjustments to the right-of-use asset may be required for items such as incentives received. The interest rate implicit in the Company’s leases is typically not readily determinable. As a result, the Company utilizes its incremental borrowing rate, which reflects the fixed rate at which the Company could borrow on a collateralized basis the amount of the lease payments in the same currency, for a similar term and in a similar economic environment. In transition to ASC 842, the Company utilized the remaining lease term of its leases in determining the appropriate incremental borrowing rates. In accordance with ASC 842, components of a lease should be allocated between lease components (e.g., land, building, etc.) and non-lease components (e.g., common area maintenance, consumables, etc.). The fixed and in-substance fixed contract consideration (including any consideration related to non-components) must be allocated based on the respective relative fair values to the lease components and non-lease components. Although separation of lease and non-lease components is required, certain expedients are available. Entities may elect the practical expedient to not separate lease and non-lease components by class of underlying asset where entities would account for each lease component and the related non-lease component together as a single component. For new and amended leases beginning in 2019 and after, the Company has elected to account for the lease and non-lease components for leases for classes of all underlying assets and allocate all of the contract consideration to the lease component only. |
Long-Lived Assets | Long-lived assets The Company reviews the recoverability of all long-lived assets, including the related useful lives, whenever events or changes in circumstances indicate that the carrying amount of a long-lived asset might not be recoverable. If required, the Company compares the estimated undiscounted future net cash flows to the related asset’s carrying value to determine whether there has been an impairment. If an asset is considered impaired, the asset is written down to fair value, which is based either on discounted cash flows or appraised values in the period the impairment becomes known. The Company believes that all long-lived assets are recoverable, and no impairment was deemed necessary at March 31, 2020 and 2019. |
Goodwill | Goodwill |
Revenue Recognition | Revenue recognition The Company applies the revenue recognition guidance in accordance with ASC 606, Revenue from Contracts with Customers When the Company enters into an arrangement that meets the definition of a collaboration under ASC 808, Collaborative Arrangements |
Deferred Revenue | Deferred revenue The Company applies the revenue recognition guidance in accordance with ASC 606. Using ASC 606, revenue that is unearned is deferred. Deferred revenue that is expected to be recognized as revenue more than one year subsequent to the balance sheet date is classified as long-term deferred revenue. |
Segment Information | Segment information Operating segments are defined as components of an enterprise (business activity from which it earns revenue and incurs expenses) about which discrete financial information is available and regularly reviewed by the chief operating decision maker in deciding how to allocate resources and in assessing performance. The Company’s chief decision maker, who is the Chief Executive Officer, reviews operating results to make decisions about allocating resources and assessing performance for the entire Company. The Company views its operations and manages its business as one operating segment. |
Comprehensive Loss | Comprehensive loss The Company had no items of comprehensive loss other than its net loss for each period presented. |
Recent Accounting Pronouncements | Recent accounting pronouncements From time to time, new accounting pronouncements are issued by the FASB and are adopted by the Company as of the specified effective date. Recently adopted accounting pronouncements In November 2018, the FASB issued ASU 2018-18, Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606 In January 2017, the FASB issued ASU No. 2017-04, Intangibles — Goodwill and Other (Topic 350). |
Significant Accounting Polici_3
Significant Accounting Policies (Tables) | 3 Months Ended |
Mar. 31, 2020 | |
Accounting Policies [Abstract] | |
Amortized Cost Basis, Aggregate Fair Value, Unrealized (Gains)/Losses and Net Carrying Value of Investments in Held-to-maturity Securities | The following tables provide the amortized cost basis, aggregate fair value, unrealized gains/losses, and the net carrying value of investments in held-to-maturity securities as of March 31, 2020 and December 31, 2019: March 31, 2020 Amortized Aggregate Unrealized Unrealized Net Carrying Cost Fair Value Gains Losses Value Marketable securities: Commercial paper $ 7,478,185 $ 7,478,185 $ — $ — $ 7,478,185 Marketable securities total $ 7,478,185 $ 7,478,185 $ — $ — $ 7,478,185 December 31, 2019 Amortized Aggregate Unrealized Unrealized Net Carrying Cost Fair Value Gains Losses Value Marketable securities: Corporate bonds/notes $ 2,701,114 $ 2,700,678 $ 436 $ — $ 2,701,114 Commercial paper 19,245,921 19,245,921 — — 19,245,921 U.S. government agency securities 2,494,485 2,495,675 — (1,190 ) 2,494,485 Marketable securities total $ 24,441,520 $ 24,442,274 $ 436 $ (1,190 ) $ 24,441,520 |
Accrued Expenses and Other Li_2
Accrued Expenses and Other Liabilities (Tables) | 3 Months Ended |
Mar. 31, 2020 | |
Payables And Accruals [Abstract] | |
Schedule of Accrued Expenses and Other Liabilities | Accrued expenses and other liabilities consist of the following: March 31, 2020 December 31, 2019 Research and development costs and other accrued expenses $ 3,090,336 $ 3,824,950 Accrued bonus 504,600 — Professional fees 281,050 314,213 Vacation pay 60,247 — $ 3,936,233 $ 4,139,163 |
Net Loss Per Share of Common _2
Net Loss Per Share of Common Stock (Tables) | 3 Months Ended |
Mar. 31, 2020 | |
Earnings Per Share [Abstract] | |
Computation of Basic and Diluted Loss Per Share | The following table sets forth the computation of basic and diluted loss per share for common stockholders: Three Months Ended March 31, 2020 2019 Net loss $ (12,151,165 ) $ (15,827,200 ) Weighted average shares of common stock outstanding 39,177,592 38,968,110 Net loss per share of common stock – basic and diluted $ (0.31 ) $ (0.41 ) |
Securities Excluded from Calculation of Weighted Average Shares Outstanding as their Effect is Antidilutive | The following securities outstanding at March 31, 2020 and 2019 have been excluded from the calculation of weighted average shares outstanding as their effect on the calculation of loss per share is antidilutive: Three Months Ended March 31, 2020 2019 Common stock options 8,799,959 8,378,672 Restricted stock units 68,650 127,300 Common stock warrants 40,790 40,790 |
Stock Award Plan and Stock-Ba_2
Stock Award Plan and Stock-Based Compensation (Tables) | 3 Months Ended |
Mar. 31, 2020 | |
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract] | |
Schedule of Stock Option Activity for Employees and Non-Employees | Stock option activity for employees and non-employees for the three months ended March 31, 2020 is as follows: Shares Issuable Pursuant to Stock Options Weighted- Average Exercise Price Weighted- Average Remaining Contractual Terms (years) Total Intrinsic Value (in thousands) Outstanding January 1, 2020 9,040,328 $ 6.98 7.3 $ 7,420 Granted — $ — Exercised (135,013 ) $ 5.91 Forfeited (105,356 ) $ 9.63 Outstanding March 31, 2020 8,799,959 $ 6.96 7.1 $ 1,625 Exercisable March 31, 2020 5,614,559 $ 6.69 6.4 $ 1,586 Available for future grant 245,354 |
Schedule of RSU Activity | RSU activity under the Plan for the three months ended March 31, 2020 is as follows: Weighted- Average Grant Date RSUs Fair Value Unvested January 1, 2020 68,650 $ 11.29 Granted — $ — Vested — $ — Forfeited — $ — Unvested March 31, 2020 68,650 $ 11.29 |
Schedule of Stock-Based Compensation Expense Included in the Company's Consolidated Statements of Operations | The following table presents stock-based compensation expense included in the Company’s consolidated statements of operations: Three Months Ended March 31, 2020 2019 Research and development $ 681,613 $ 700,263 General and administrative 1,516,574 1,761,436 Total $ 2,198,187 $ 2,461,699 |
Leases (Tables)
Leases (Tables) | 3 Months Ended |
Mar. 31, 2020 | |
Leases [Abstract] | |
Summary of the Sublease Costs | The following table contains a summary of the Sublease costs recognized under ASC 842 and other information pertaining to the Company’s operating Sublease for the three months ended March 31, 2020: Three Months Ended March 31, 2020 Sublease cost Operating Sublease cost $ 44,817 Total Sublease cost $ 44,817 Other information Operating cash flows used for operating Sublease $ 47,384 Weighted average remaining Sublease term 1.3 years Weighted average discount rate 10% |
Future Minimum Sublease Payments Under Non-cancelable Operating Sublease | Future minimum Sublease payments under the Company’s non-cancelable operating Sublease as of March 31, 2020 and December 31, 2019 are as follows: Future Operating Sublease Payments Three Months Ended March 31, 2020 2020 (excluding the three months ended March 31, 2020) 144,620 2021 114,018 Thereafter — Total Sublease payments $ 258,638 Less: imputed interest (15,523 ) Total operating Sublease liabilities at March 31, 2020 $ 243,115 Future Operating Sublease Payments Year Ended December 31, 2019 2020 192,004 2021 114,018 Thereafter — Total Sublease payments $ 306,022 Less: imputed interest (21,892 ) Total operating Sublease liabilities at December 31, 2019 $ 284,130 |
NATURE OF OPERATIONS AND LIQU_2
NATURE OF OPERATIONS AND LIQUIDITY - Additional Information (Details) | 3 Months Ended | ||
Mar. 31, 2020USD ($)License | Mar. 31, 2019USD ($) | Dec. 31, 2019USD ($) | |
Nature Of Operations And Liquidity [Line Items] | |||
Accumulated deficit | $ 298,887,383 | $ 286,736,218 | |
Net cash used in operating activities | 9,202,397 | $ 9,600,592 | |
Cash, cash equivalents, restricted cash and marketable securities | $ 37,600,000 | ||
Development-stage Proprietary Compounds | |||
Nature Of Operations And Liquidity [Line Items] | |||
Number of licenses acquired | License | 4 |
SIGNIFICANT ACCOUNTING POLICI_4
SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Details) | 3 Months Ended | 12 Months Ended | |
Mar. 31, 2020USD ($)Segment | Mar. 31, 2019USD ($) | Dec. 31, 2019USD ($) | |
Significant Accounting Policies [Line Items] | |||
Restricted cash balances as collateral for corporate credit cards | $ 100,000 | $ 100,000 | $ 100,000 |
Marketable securities, weighted average remaining maturity | 2 months 3 days | ||
Asset impairment charges | $ 19,000,000 | ||
Equipment estimated useful life | 3 years | ||
Impairment of Long-Lived Assets | $ 0 | 0 | |
Impairment of goodwill | 0 | 0 | |
Revenues from product sales to date | $ 0 | ||
Number of operating segments | Segment | 1 | ||
In-Process Research and Development | |||
Significant Accounting Policies [Line Items] | |||
Asset impairment charges | $ 0 | $ 0 |
SIGNIFICANT ACCOUNTING POLICI_5
SIGNIFICANT ACCOUNTING POLICIES - Amortized Cost Basis, Aggregate Fair Value, Unrealized (Gains)/Losses and Net Carrying Value of Investments in Held-to-maturity Securities (Details) - USD ($) | Mar. 31, 2020 | Dec. 31, 2019 |
Schedule Of Held To Maturity Securities [Line Items] | ||
Marketable securities, Amortized Cost | $ 7,478,185 | $ 24,441,520 |
Marketable securities, Aggregate Fair Value | 7,478,185 | 24,442,274 |
Marketable securities, Unrealized Gains | 436 | |
Marketable securities, Unrealized Losses | (1,190) | |
Marketable securities, Net Carrying Value | 7,478,185 | 24,441,520 |
Corporate Bonds/Notes | ||
Schedule Of Held To Maturity Securities [Line Items] | ||
Marketable securities, Amortized Cost | 2,701,114 | |
Marketable securities, Aggregate Fair Value | 2,700,678 | |
Marketable securities, Unrealized Gains | 436 | |
Marketable securities, Net Carrying Value | 2,701,114 | |
Commercial Paper | ||
Schedule Of Held To Maturity Securities [Line Items] | ||
Marketable securities, Amortized Cost | 7,478,185 | 19,245,921 |
Marketable securities, Aggregate Fair Value | 7,478,185 | 19,245,921 |
Marketable securities, Net Carrying Value | $ 7,478,185 | 19,245,921 |
U.S. government Agency Securities | ||
Schedule Of Held To Maturity Securities [Line Items] | ||
Marketable securities, Amortized Cost | 2,494,485 | |
Marketable securities, Aggregate Fair Value | 2,495,675 | |
Marketable securities, Unrealized Losses | (1,190) | |
Marketable securities, Net Carrying Value | $ 2,494,485 |
ACCRUED EXPENSES AND OTHER LI_3
ACCRUED EXPENSES AND OTHER LIABILITIES - Accrued Expenses and Other Liabilities (Details) - USD ($) | Mar. 31, 2020 | Dec. 31, 2019 |
Payables And Accruals [Abstract] | ||
Research and development costs and other accrued expenses | $ 3,090,336 | $ 3,824,950 |
Accrued bonus | 504,600 | |
Professional fees | 281,050 | 314,213 |
Vacation pay | 60,247 | |
Accrued expenses and other liabilities | $ 3,936,233 | $ 4,139,163 |
NET LOSS PER SHARE OF COMMON _3
NET LOSS PER SHARE OF COMMON STOCK - Computation of Basic and Diluted Loss Per Share (Details) - USD ($) | 3 Months Ended | |
Mar. 31, 2020 | Mar. 31, 2019 | |
Earnings Per Share [Abstract] | ||
Net loss | $ (12,151,165) | $ (15,827,200) |
Weighted average shares of common stock outstanding | 39,177,592 | 38,968,110 |
Net loss per share of common stock – basic and diluted | $ (0.31) | $ (0.41) |
NET LOSS PER SHARE OF COMMON _4
NET LOSS PER SHARE OF COMMON STOCK - Securities Excluded from Calculation of Weighted Average Shares Outstanding as their Effect is Antidilutive (Details) - shares | 3 Months Ended | |
Mar. 31, 2020 | Mar. 31, 2019 | |
Common Stock Options | ||
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] | ||
Securities outstanding excluded from the calculation of weighted average shares outstanding | 8,799,959 | 8,378,672 |
Restricted Stock Units | ||
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] | ||
Securities outstanding excluded from the calculation of weighted average shares outstanding | 68,650 | 127,300 |
Common Stock Warrants | ||
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] | ||
Securities outstanding excluded from the calculation of weighted average shares outstanding | 40,790 | 40,790 |
CO-DEVELOPMENT AND LICENSE AG_2
CO-DEVELOPMENT AND LICENSE AGREEMENT - Additional Information (Details) - USD ($) $ / shares in Units, shares in Millions | Aug. 29, 2017 | Jul. 06, 2016 | Jul. 07, 2014 | Apr. 30, 2020 | Jan. 31, 2020 | Mar. 31, 2020 | Mar. 31, 2019 | Dec. 31, 2020 | Dec. 31, 2019 |
Co-development and license agreement | |||||||||
Research and development expense | $ 8,082,510 | $ 11,606,197 | |||||||
Phase 3 Insomnia Trail | |||||||||
Co-development and license agreement | |||||||||
Percentage of milestone payment on aggregate product development cost | 40.00% | ||||||||
Janssen | Phase 3 Insomnia Trail | |||||||||
Co-development and license agreement | |||||||||
Milestone method payments | $ 40,000,000 | ||||||||
Percentage of milestone payment on aggregate product development cost | 40.00% | ||||||||
Development cost invoiced | $ 3,400,000 | $ 6,500,000 | |||||||
Janssen | Phase 3 Insomnia Trail | Forecast | |||||||||
Co-development and license agreement | |||||||||
Estimated development costs | $ 100,000,000 | ||||||||
Janssen | Phase 3 Insomnia Trail | Subsequent Event | |||||||||
Co-development and license agreement | |||||||||
Development cost invoiced | $ 3,100,000 | ||||||||
Janssen | Seltorexant | Co-Development and License Agreement | |||||||||
Co-development and license agreement | |||||||||
Payment of license fee | $ 22,000,000 | ||||||||
Payment of development costs | $ 3,500,000 | ||||||||
Direct expenses incurred | $ 300,000 | ||||||||
Research and development expense | $ 0 | $ 0 | |||||||
Janssen | Seltorexant | Amendment to Co-Development and License Agreement | |||||||||
Co-development and license agreement | |||||||||
Upfront payment | $ 30,000,000 | ||||||||
Revenue recognition, milestone method, factors | The $30 million payment and $11.2 million in previously accrued collaborative expenses, which were forgiven upon the effective date of the Amendment, are earned and recognized as revenue as the services are performed from the commencement of Phase 3 development to the completion of the development activities using the proportional performance method. | ||||||||
Accrued collaborative expenses | 11,200,000 | ||||||||
Upfront payment received | $ 30,000,000 | $ 30,000,000 | |||||||
Previously accrued collaborative expenses recognized as revenue | $ 11,200,000 | $ 11,200,000 | |||||||
Janssen | Seltorexant | Amendment to Co-Development and License Agreement | Phase 3 Insomnia Trail | |||||||||
Co-development and license agreement | |||||||||
Payment start of Phase | 20,000,000 | ||||||||
Payment upon enrollment of patients | $ 20,000,000 | ||||||||
Percentage of patients to be enrolled | 50.00% | ||||||||
Johnson & Johnson Innovation-JJDC Inc | |||||||||
Co-development and license agreement | |||||||||
Stock repurchased | 3.9 | ||||||||
Stock repurchased price per share | $ 0.0001 | ||||||||
Aggregate purchase price | $ 389 |
STOCKHOLDERS' EQUITY - Term Loa
STOCKHOLDERS' EQUITY - Term Loan Warrants - Additional Information (Details) | Jan. 16, 2015USD ($)Tranche$ / sharesshares |
Class Of Warrant Or Right [Line Items] | |
Fair value of warrants estimated | $ | $ 200,000 |
Warrant | |
Class Of Warrant Or Right [Line Items] | |
Expiration anniversary date of issuance | 10 years |
Warrant | Valuation Technique, Option Pricing Model | Measurement Input, Price Volatility | |
Class Of Warrant Or Right [Line Items] | |
Alternative investment, measurement input | 100.8 |
Warrant | Valuation Technique, Option Pricing Model | Measurement Input, Risk Free Interest Rate | |
Class Of Warrant Or Right [Line Items] | |
Alternative investment, measurement input | 1.83 |
Warrant | Valuation Technique, Option Pricing Model | Measurement Input, Expected Term | |
Class Of Warrant Or Right [Line Items] | |
Expected life | 10 years |
Warrant | Valuation Technique, Option Pricing Model | Measurement Input, Expected Dividend Payment | |
Class Of Warrant Or Right [Line Items] | |
Expected dividend | $ / shares | $ 0 |
Term Loan | Term A Loans | |
Class Of Warrant Or Right [Line Items] | |
Shares of common stock to purchase by warrant | shares | 40,790 |
Common stock exercise price per share | $ / shares | $ 5.516 |
Loan and Security Agreement | Term Loan | |
Class Of Warrant Or Right [Line Items] | |
Aggregate principal amount | $ | $ 15,000,000 |
Number of tranches | Tranche | 2 |
STOCK AWARD PLAN AND STOCK-BA_3
STOCK AWARD PLAN AND STOCK-BASED COMPENSATION - Additional Information (Details) - USD ($) $ / shares in Units, $ in Millions | 1 Months Ended | 3 Months Ended | |
Dec. 31, 2017 | Mar. 31, 2020 | Mar. 31, 2019 | |
Stock Award Plan and Stock-Based Compensation | |||
Shares issued | 0 | 0 | |
Fair value of common stock on grant date (in dollars per share) | $ 5.01 | ||
Total intrinsic value of the stock options exercised | $ 0.3 | $ 0.2 | |
Dividend yield (as a percent) | 0.00% | ||
Employee Stock Option | |||
Stock Award Plan and Stock-Based Compensation | |||
Total unrecognized compensation costs | $ 15.8 | ||
Weighted-average period over which unrecognized compensation costs is expected to be recognized | 2 years 3 months 14 days | ||
Restricted Stock Units | |||
Stock Award Plan and Stock-Based Compensation | |||
Total unrecognized compensation costs | $ 0.6 | ||
Weighted-average period over which unrecognized compensation costs is expected to be recognized | 10 months 24 days | ||
Vesting rights percentage | 25.00% | ||
Vesting period | 4 years | ||
Description of vesting rights | RSUs awarded to employees generally vest one-fourth per year over four years from the anniversary of the date of grant | ||
2013 Equity Incentive Plan | Common Stock | |||
Stock Award Plan and Stock-Based Compensation | |||
Increase in number of shares authorized for issuance | 2,500,000 | ||
2013 Equity Incentive Plan | Employee Stock Option | Common Stock | Rick Russell | |||
Stock Award Plan and Stock-Based Compensation | |||
Shares issued | 775,000 | ||
2013 Equity Incentive Plan | Restricted Stock Units | Common Stock | Rick Russell | |||
Stock Award Plan and Stock-Based Compensation | |||
Shares issued | 40,000 |
STOCK AWARD PLAN AND STOCK-BA_4
STOCK AWARD PLAN AND STOCK-BASED COMPENSATION - Stock Option Activity for Employees and Non-Employees (Details) - USD ($) $ / shares in Units, $ in Thousands | 3 Months Ended | 12 Months Ended | |
Mar. 31, 2020 | Mar. 31, 2019 | Dec. 31, 2019 | |
Shares Issuable Pursuant to Stock Options | |||
Granted (in shares) | 0 | 0 | |
Employees and Non-Employees Stock Option | |||
Shares Issuable Pursuant to Stock Options | |||
Outstanding at the beginning of period (in shares) | 9,040,328 | ||
Exercised (in shares) | (135,013) | ||
Forfeited (in shares) | (105,356) | ||
Outstanding at the end of the period (in shares) | 8,799,959 | 9,040,328 | |
Exercisable at the end of the period (in shares) | 5,614,559 | ||
Available for future grant (in shares) | 245,354 | ||
Weighted-Average Exercise Price | |||
Outstanding at the beginning of period (in dollars per share) | $ 6.98 | ||
Exercised (in dollars per share) | 5.91 | ||
Forfeited (in dollars per share) | 9.63 | ||
Outstanding at the end of the period (in dollars per share) | 6.96 | $ 6.98 | |
Exercisable at the end of the period (in dollars per share) | $ 6.69 | ||
Weighted-Average Remaining Contractual Term Outstanding (Years) | 7 years 1 month 6 days | 7 years 3 months 18 days | |
Weighted-Average Remaining Contractual Term Exercisable (Years) | 6 years 4 months 24 days | ||
Total Intrinsic Value Outstanding at the begining of period | $ 7,420 | ||
Total Intrinsic Value Outstanding at the end of period | 1,625 | $ 7,420 | |
Total Intrinsic Value Exercisable | $ 1,586 |
STOCK AWARD PLAN AND STOCK-BA_5
STOCK AWARD PLAN AND STOCK-BASED COMPENSATION - Schedule of RSU Activity (Details) - Restricted Stock Units - $ / shares | Mar. 31, 2020 | Dec. 31, 2019 |
Stock Options | ||
Unvested at the beginning of the period (in shares) | 68,650 | |
Unvested at the end of the period (in shares) | 68,650 | 68,650 |
Weighted-Average Grant Date Fair Value | ||
Unvested at the beginning of the period (in dollars per share) | $ 11.29 | $ 11.29 |
Unvested at the end of the period (in dollars per share) | $ 11.29 |
STOCK AWARD PLAN AND STOCK-BA_6
STOCK AWARD PLAN AND STOCK-BASED COMPENSATION - Schedule of Stock-Based Compensation Expense Included in the Company's Consolidated Statements of Operations (Details) - USD ($) | 3 Months Ended | |
Mar. 31, 2020 | Mar. 31, 2019 | |
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items] | ||
Stock based compensation expense | $ 2,198,187 | $ 2,461,699 |
Research and Development | ||
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items] | ||
Stock based compensation expense | 681,613 | 700,263 |
General and Administrative | ||
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items] | ||
Stock based compensation expense | $ 1,516,574 | $ 1,761,436 |
COMMITMENTS AND CONTINGENCIES -
COMMITMENTS AND CONTINGENCIES - Additional Information (Details) - Janssen - USD ($) $ in Millions | 1 Months Ended | 3 Months Ended | 12 Months Ended | |
Apr. 30, 2020 | Jan. 31, 2020 | Mar. 31, 2020 | Dec. 31, 2020 | |
Loss Contingencies [Line Items] | ||||
Percentage of development costs related to joint development of products | 60.00% | |||
Phase 3 Insomnia Trail | ||||
Loss Contingencies [Line Items] | ||||
Percentage of development costs related to joint development of products | 40.00% | |||
Development cost invoiced | $ 3.4 | $ 6.5 | ||
Phase 3 Insomnia Trail | Forecast | ||||
Loss Contingencies [Line Items] | ||||
Estimated development costs | $ 100 | |||
Phase 3 Insomnia Trail | Subsequent Event | ||||
Loss Contingencies [Line Items] | ||||
Development cost invoiced | $ 3.1 |
LEASES - Additional Information
LEASES - Additional Information (Details) - Office Sublease Agreement - Profitect, Inc | Oct. 02, 2017USD ($)ft² | Mar. 31, 2020 |
Operating Leases [Line Items] | ||
Sublease rentable square feet | ft² | 5,923 | |
Lease description | The term of the Sublease began on November 1, 2017 and will expire on July 31, 2021 (the “Term”), with a monthly rental rate starting at $14,808 and escalating to a maximum monthly rental rate of $16,288 in the final 12 months of the Term. | |
Lease commencement date | Nov. 1, 2017 | |
Sublease expire date | Jul. 31, 2021 | |
Minimum | ||
Operating Leases [Line Items] | ||
Monthly rental rate | $ 14,808 | |
Maximum | ||
Operating Leases [Line Items] | ||
Monthly rental rate | $ 16,288 |
LEASES - Summary of the Subleas
LEASES - Summary of the Sublease Costs (Details) - Office Sublease Agreement | 3 Months Ended |
Mar. 31, 2020USD ($) | |
Operating Leases [Line Items] | |
Operating Sublease cost | $ 44,817 |
Total Sublease cost | 44,817 |
Operating cash flows used for operating Sublease | $ 47,384 |
Weighted average remaining Sublease term | 1 year 3 months 18 days |
Weighted average discount rate | 10.00% |
LEASES - Future Minimum Subleas
LEASES - Future Minimum Sublease Payments Under Non-cancelable Operating Sublease (Details) - Office Sublease Agreement - USD ($) | Mar. 31, 2020 | Dec. 31, 2019 |
Operating Leases [Line Items] | ||
2020 | $ 144,620 | $ 192,004 |
2021 | 114,018 | 114,018 |
Total Sublease payments | 258,638 | 306,022 |
Less: imputed interest | (15,523) | (21,892) |
Total operating Sublease liabilities | $ 243,115 | $ 284,130 |
RELATED PARTY TRANSACTIONS - Ad
RELATED PARTY TRANSACTIONS - Additional Information (Details) - V - Watch SA $ in Thousands | 1 Months Ended |
Jan. 31, 2016USD ($) | |
Related Party Transaction [Line Items] | |
Services agreement | $ 105 |
Minimum | |
Related Party Transaction [Line Items] | |
Percentage of outstanding capital stock | 10.00% |